Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 124,998 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $18.44, for a total value of $2,304,963.12. Following the completion of the sale, the chief executive officer directly owned 2,459,245 shares of the company’s stock, valued at approximately $45,348,477.80. This trade represents a 4.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock opened at $16.47 on Friday. Adaptive Biotechnologies Corporation has a one year low of $6.26 and a one year high of $20.76. The business’s 50 day simple moving average is $17.10 and its two-hundred day simple moving average is $15.16. The stock has a market capitalization of $2.51 billion, a P/E ratio of -30.50 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The firm had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. During the same quarter last year, the business earned ($0.23) earnings per share. The business’s revenue was up 51.0% on a year-over-year basis. Sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADPT. Sound Income Strategies LLC bought a new stake in shares of Adaptive Biotechnologies during the 3rd quarter valued at $30,000. Assetmark Inc. lifted its position in Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after acquiring an additional 2,708 shares during the period. Smartleaf Asset Management LLC boosted its stake in Adaptive Biotechnologies by 593.5% during the third quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock worth $59,000 after acquiring an additional 3,371 shares in the last quarter. Caxton Associates LLP purchased a new stake in Adaptive Biotechnologies in the first quarter worth about $93,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Adaptive Biotechnologies by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock valued at $120,000 after purchasing an additional 1,532 shares in the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ADPT. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 7th. Morgan Stanley initiated coverage on Adaptive Biotechnologies in a research report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price objective on the stock. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. BTIG Research raised their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.22.

Key Headlines Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results beat expectations — Adaptive reported EPS of ($0.09) vs. a consensus loss of ($0.19) and revenue of $71.7M vs. consensus ~$59.4M, showing stronger-than-expected commercial traction. MarketBeat Earnings Coverage
• Neutral Sentiment: Company published full Q4 and FY2025 financial results, slide deck and conference call materials for review — useful for modeling guidance and revenue composition but no new long‑term guidance announced in headlines. GlobeNewswire Press Release
• Neutral Sentiment: Analyst positioning remains mildly constructive (consensus “Moderate Buy” and an average price target near the mid‑teens), which can provide support if execution continues. Analyst Coverage Note
• Negative Sentiment: Insider selling: CEO Chad Robins disclosed sale of ~125k shares (~$2.3M at ~$18.44) and other insiders (Harlan Robins) sold additional shares this week — large insider sales can signal tax/liquidity moves but often weigh on near‑term sentiment. SEC Filing (Insider Sales)
• Negative Sentiment: Despite the beat, Adaptive remains unprofitable (negative net margin and ROE), and investors may be focused on the path to consistent profitability and cash flow; that concern likely contributed to the stock decline today. MarketBeat Company Snapshot

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.